# A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

> **NCT07567781** · PHASE1 · RECRUITING · sponsor: **AbbVie** · enrollment: 12 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ABBV-722
- **DRUG:** Midazolam
- **DRUG:** Metformin
- **DRUG:** Digoxin
- **DRUG:** Pitavastatin
- **DRUG:** Sitagliptin

## Key facts

- **NCT ID:** NCT07567781
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2026-07
- **Final completion:** 2026-07
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07567781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07567781, "A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07567781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*